Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Atiprimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 3/20 | 0.41 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.33 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.33 |
| ▸ | S1PR4 known ✓ | O95977 | 1/20 | 0.31 |
| ▸ | S1PR1 known ✓ | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 known ✓ | Q99500 | 1/20 | 0.31 |
| ▸ | S1PR5 known ✓ | Q9H228 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atiprimod SCHEMBL93890 | 0.99 | OPRM1 (0.41) | OPRM1OPRL1DRD2DRD3ALOX15 | |
| Atiprimod SCHEMBL1650509 | 0.96 | OPRM1 (0.40) | OPRM1OPRL1DRD2DRD3ALOX15 | |
| Atiprimod SCHEMBL8597011 | 0.88 | OPRM1 (0.38) | OPRM1OPRL1S1PR4S1PR1S1PR3 | |
| Hydrochloric Acid SCHEMBL6950425 | 0.87 | ALOX15 (0.45) | OPRM1OPRL1DRD2DRD3ALOX15 | |
| SCHEMBL7920522 | 0.86 | ALOX15 (0.46) | OPRM1OPRL1DRD2DRD3ALOX15 | |
| Hydrochloric Acid SCHEMBL8740646 | 0.81 | OPRM1 (0.40) | OPRM1OPRL1ALOX15TSHR | |
| Hydrochloric Acid SCHEMBL9299175 | 0.81 | OPRM1 (0.40) | OPRM1OPRL1DRD2DRD3TSHR | |
| SCHEMBL14595479 | 0.81 | OPRM1 (0.43) | OPRM1OPRL1DRD2DRD3ALOX15 | |
| Hydrochloric Acid SCHEMBL9452580 | 0.80 | OPRM1 (0.40) | OPRM1OPRL1DRD2DRD3TSHR | |
| SCHEMBL14595476 | 0.80 | OPRM1 (0.48) | OPRM1OPRL1DRD2DRD3ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233870-A2 | ANTI-CANCER EFFECTS OF JAK2 INHIBITORS IN COMBINATION WITH THALIDOMIDE DERIVATIVES AND GLUCOCORTICOIDS | Onco Tracker, Inc. (US) | 2023-08-30 | — | — | EP | claimed |
| US-20230233579-A1 | ANTI-CANCER EFFECTS OF JAK2 INHIBITORS IN COMBINATION WITH THALIDOMIDE DERIVATIVES AND GLUCOCORTICOIDS | Oncotracker, Inc. | 2023-07-27 | — | — | US | claimed |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2019-04-30 | — | — | US | claimed |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2018-07-05 | — | — | US | claimed |
| EP-3309163-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE Industries, Ltd. (JP) | 2018-04-18 | — | — | EP | claimed |
| US-20170106003-A1 | ANTI-CANCER EFFECTS OF JAK2 INHIBITORS IN COMBINATION WITH THALIDOMIDE DERIVATIVES AND GLUCOCORTICOIDS | INSTITUTE FOR MYELOMA & BONE CANCER RESEARCH (US) | 2017-04-20 | — | — | US | claimed |
| EP-3148545-A2 | ANTI-CANCER EFFECTS OF JAK2 INHIBITORS IN COMBINATION WITH THALIDOMIDE DERIVATIVES AND GLUCOCORTICOIDS | Institute for Myeloma & Bone Cancer Research (US) | 2017-04-05 | — | — | EP | claimed |
| WO-2015184087-A9 | ANTI-CANCER EFFECTS OF JAK2 INHIBITORS IN COMBINATION WITH THALIDOMIDE DERIVATIVES AND GLUCOCORTICOIDS | INSTITUTE FOR MYELOMA & BONE CANCER RESEARCH (US) | 2016-04-21 | — | — | WO | claimed |
| WO-2015184087-A2 | ANTI-CANCER EFFECTS OF JAK2 INHIBITORS IN COMBINATION WITH THALIDOMIDE DERIVATIVES AND GLUCOCORTICOIDS | INSTITUTE FOR MYELOMA & BONE CANCER RESEARCH (US) | 2015-12-03 | — | — | WO | claimed |
| EP-0572537-B1 | CYTOKINE INHIBITORS | ANORMED INC (CA) | 1999-11-17 | — | — | EP | claimed |
| US-12304913-B2 | Dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2025-05-20 | — | — | US | disclosed |
| CN-118562694-A | Microorganism expressing exogenous protein and use thereof | 丽必微股份有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240218039-A1 | MICROORGANISM EXPRESSING VASOACTIVE INTESTINAL PEPTIDE, AND USE THEREOF | MEDYTOX INC. (KR) | 2024-07-04 | — | — | US | disclosed |
| CN-113348241-B | Microorganism expressing exogenous protein and use thereof | 丽必微股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-26 | — | — | US | disclosed |
| EP-0711160-A1 | METHOD OF INHIBITING THE REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUSES WITH SUBSTITUTED AZASPIRANES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-05-15 | — | — | EP | disclosed |
| WO-1996003126-A1 | METHOD OF TREATING OPPORTUNISTIC INFECTIONS WITH AZASPIRANES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-02-08 | — | — | WO | disclosed |
| WO-1995003049-A1 | METHODS OF TREATING HIV WITH AZASPIRANES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-02 | — | — | WO | disclosed |
| WO-1995003042-A1 | METHOD OF INHIBITING THE REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUSES WITH SUBSTITUTED AZASPIRANES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-02 | — | — | WO | disclosed |
| WO-1995003041-A1 | METHOD OF INHIBITING THE PRODUCTION OF HUMAN IMMUNODEFICIENCY VIRUSES WITH SUBSTITUTED AZASPIRANES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12304913-B2 | Dihydropyrrolopyrazole derivative | CBR3, SLC13A3, CYP3A5 | OPRM1 1111/4885DRD2 114/4885DRD3 17/4885 |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | QDPR, CYP11B2, CYP4F3 | OPRM1 2953/4885DRD2 566/4885DRD3 251/4885 |
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | RORB, RORC, RORA | OPRM1 639/4885DRD2 2788/4885DRD3 2458/4885 |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | QDPR, CYP11B2, CYP4F3 | OPRM1 2953/4885DRD2 566/4885DRD3 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.